Related Experiment Video
Updated: Jan 10, 2026
Generation and Recovery of β-cell Spheroids From Step-growth PEG-peptide Hydrogels
Published on: December 6, 2012
Anti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells
Adrienne E Widener1,2,3, Cameron T Manson1, Jessie M Barra2,3
1J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.
Abstract:
Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells, leaving patients dependent on exogenous insulin and at risk of severe hypoglycemic episodes. Stem cell-derived beta-like cells (sBCs) offer a promising approach for beta cell replacement therapy, but clinical translation is limited by immune-mediated rejection, recurrent autoimmunity, and inhospitable transplantation sites. Biomaterials have been investigated to provide localized immune-isolation and immunomodulation, but foreign body responses and rapid depletion of therapeutic agents remain as obstacles to clinical translation. Here, we present a microporous annealed particle (MAP) hydrogel functionalized with an anti-CD3 monoclonal antibody (αCD3) to provide a localized immunomodulatory microenvironment for beta cell replacement therapy. MAP hydrogels consisting of guest-host interlinked polyethylene glycol-maleimide (PEG-MAL) microgels supported rapid vascularization, minimal foreign body response, and engraftment of syngeneic islets in mice. αCD3 MAP hydrogel halted T cell migration in vitro and protected transplanted sBCs from immune-mediated destruction by HLA-matched diabetogenic T cells in vivo. Subcutaneous αCD3 functionalized MAP hydrogel also protected the endogenous islets in the pancreas, demonstrating potential for systemic immune modulation. These findings establish αCD3 MAP hydrogels as a promising strategy for localized immune modulation in cell replacement therapy.
Insights
Microporous annealed particle (MAP) hydrogels functionalized with anti-CD3 antibodies create a localized immune-shield for transplanted cells. This strategy shows promise for protecting beta cells and advancing cell replacement therapy for type 1 diabetes.
Area of Science:
- Biomaterials Science
- Immunology
- Regenerative Medicine
Background:
- Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic beta cells, necessitating insulin therapy and risking hypoglycemia.
- Stem cell-derived beta-like cells (sBCs) offer potential for T1D treatment but face challenges like immune rejection and poor transplantation sites.
- Existing biomaterials for immune modulation struggle with foreign body responses and rapid therapeutic agent depletion.
Purpose of the Study:
- To develop a localized immunomodulatory microenvironment for beta cell replacement therapy using functionalized hydrogels.
- To assess the efficacy of anti-CD3 monoclonal antibody (αCD3) functionalized microporous annealed particle (MAP) hydrogels in preventing immune-mediated destruction of transplanted cells.
Main Methods:
- Fabrication of MAP hydrogels using guest-host interlinked polyethylene glycol-maleimide (PEG-MAL) microgels.
- Functionalization of MAP hydrogels with an anti-CD3 monoclonal antibody (αCD3).
- In vitro assessment of T cell migration inhibition and in vivo evaluation of transplanted sBC protection in mice.
Main Results:
- MAP hydrogels promoted rapid vascularization and exhibited a minimal foreign body response in mice.
- αCD3 MAP hydrogels effectively halted T cell migration in vitro.
- Transplanted sBCs were protected from immune-mediated destruction by diabetogenic T cells in vivo.
- Subcutaneous αCD3 MAP hydrogels also protected endogenous pancreatic islets, suggesting systemic immune modulation potential.
Conclusions:
- αCD3 functionalized MAP hydrogels provide a promising platform for localized immune modulation in cell replacement therapies.
- This approach addresses key barriers to clinical translation, including immune rejection and foreign body response.
- The findings support the potential of αCD3 MAP hydrogels for treating type 1 diabetes and other autoimmune diseases.
